Prometic Life Sciences (TSX:PLI; OTCQX:PFSCF) named Prof. Simon Best as interim CEO, effective immediately, succeeding Pierre Laurin, who has stepped down from his management and board responsibilities.
Prof. Best has been chairman of Prometic since May 2014. He has more than 30 years of global life sciences experience, with a focus on business development, strategic planning and product commercialization. He has served as CEO of several biotech companies and as both vice chairman of the U.S. Biotechnology Industry Organization and chairman of the UK BioIndustry Association.
Prometic is appointing a top-tier global search firm to find a permanent CEO.
“We recognize and deeply appreciate the valuable contribution that Pierre has made in founding and building Prometic during the past 24 years,” Prof. Best said in a statement.
Under his leadership, Prometic advanced its lead assets, Ryplazim and PBI-4050, towards commercialization and developed a pipeline of promising follow-up compounds. “We are pleased that Pierre has agreed to support Prometic during the transition to new leadership,” Prof. Best added.
Prometic also named Zachary Newton to the board as the second designee of Structured Alpha, an affiliate of Thomvest Asset Management.
“I look forward to supporting Prometic in its leadership transition and evaluation of a new strategic direction,” Mr. Newton said. “Prof. Best and his management team have Thomvest’s full support, and we are confident in Prometic’s future.”
